Newbury Pharmaceuticals AB

NEWBRY

SE0015244884

Drug Retailers

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 25/06/2024 BST			5-day change	1st Jan Change
3.4 ^SEK	+6.25%		+3.66%	+10.75%

04-10	Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI
02-22	Newbury Pharmaceuticals Secures SEK9 Million Sales Order	MT

Newbury Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended November 30, 2022

January 11, 2023 at 07:00 am

Newbury Pharmaceuticals AB (publ) reported earnings results for the first quarter ended November 30, 2022. For the first quarter, the company reported sales was SEK 0.258 million. Net loss was SEK 5.74 million compared to SEK 3.74 million a year ago.

Latest news about Newbury Pharmaceuticals AB

Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	04-10	CI
Newbury Pharmaceuticals Secures SEK9 Million Sales Order	02-22	MT
Newbury Pharmaceuticals Receives International Sales Order Valued At 8.8 Million	02-22	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended November 30, 2023	01-10	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Full Year Ended August 31, 2023	11/10/23	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	11/10/23	CI
Newbury, Amarox Sign Distribution Deal for Sweden, Denmark	06/10/23	MT
Newbury Signs Contract with Amarox Limited to Represent and Distribute Their Products in Sweden and Denmark	06/10/23	CI
Newbury Pharmaceuticals Strengthens its Portfolio with Levodopa/Benserazide	22/09/23	CI
Newbury Secures Access to Hospital Product Portfolio in New Partnership	23/08/23	MT
Newbury Pharmaceuticals AB Gains Access to the Nordic Hospital Market with A New Strategic Partnership for Prescription Medicine	23/08/23	CI
Newbury Pharmaceuticals Gets OK to Sell Peptide Product in Sweden	19/07/23	MT
Newbury Pharmaceuticals Announces the Marketing Authorization of Desmopressin Newbury 60, 120 & 240 Mg Sublingual Tablets in Sweden	19/07/23	CI
Newbury Pharmaceuticals AB Provides Earnings Guidance for the Year 2028	16/06/23	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	14/06/23	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	12/04/23	CI
Newbury Pharmaceuticals Announces the Marketing Authorization of Lapatinib Newbury 250 Mg Film-Coated Tablets in Sweden	24/03/23	CI
Newbury Pharmaceuticals' MS Treatment Receives Marketing Authorization in Sweden	06/03/23	MT
Newbury Pharmaceuticals Announces the Marketing Authorization of Dimethyl Fumarate Newbury 120 & 240 Mg Hard Capsule in Sweden	06/03/23	CI
Certain Ordinary Shares of Newbury Pharmaceuticals AB are subject to a Lock-Up Agreement Ending on 27-JAN-2023.	26/01/23	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended November 30, 2022	11/01/23	CI
Newbury Pharmaceuticals Receives Orders for International Markets Covering Shipments During 2023	09/01/23	CI
Newbury Pharmaceuticals Gets Marketing Approval in Sweden for Multiple Sclerosis Drug	27/12/22	MT
Newbury Expands Its Portfolio with Two Ready to Launch Products	23/11/22	CI
Newbury Pharmaceuticals Announces Teriflunomide Newbury Approved by the Norwegian Health Authorities	01/11/22	CI

Chart Newbury Pharmaceuticals AB

Duration

Period

More charts

Company Profile

Newbury Pharmaceuticals AB is a Sweden-based pharmaceutical company for specialty prescription drugs. The Companyâs existing portfolio is focused on the Scandinavian market and consists of pharmaceuticals from several therapeutic areas with oncology, rare diseases and neurology.

Sector

Drug Retailers

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Retail - Drugs without Grocery

	1st Jan change	Capi.
NEWBURY PHARMACEUTICALS AB	+10.75%	7.42M
RAIA DROGASIL S.A.	-10.31%	8.31B
AIN HOLDINGS INC.	+39.43%	1.33B
QOL HOLDINGS CO., LTD.	-9.66%	343M
NIHON CHOUZAI CO.,LTD.	+6.08%	271M
SALUS, LJUBLJANA, D. D.	+9.44%	223M
PETMED EXPRESS, INC.	-44.71%	84.89M
GREEN CROSS HEALTH LIMITED	-29.36%	67.77M
MEDICAL IKKOU GROUP CO.,LTD.	+26.51%	62.08M

Retail - Drugs without Grocery